From Tysabri to bapi and back to the drawing board: Dale Schenk speaks
This article was originally published in Scrip
Dale Schenk is the scientist behind both the hugely successful multiple sclerosis treatment Tysabri (natalizumab) and the much-hyped investigational Alzheimer's disease vaccination bapineuzumab, which crashed spectacularly in Phase III trials last year. Now heading up the newly independent Prothena, which was demerged from Elan late last year, he speaks to Scrip's Eleanor Malone as he embarks on his third adventure as a biotech entrepreneur.
You may also be interested in...
Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs.
Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.